Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer

Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer

Abstract Personalized neoantigen vaccines have shown strong immunogenicity in clinical trial, but still face various challenges in facilitating an efficient antitumor immune response. Here, a personalized neoantigen nanovaccine (PNVAC) platform for adjuvant cancer immunotherapy is generated. PNVAC t...

Full description

Bibliographic Details
Main Authors: Qin Liu, Yanhong Chu, Jie Shao, Hanqing Qian, Ju Yang, Huizi Sha, Lanqi Cen, Manman Tian, Qiuping Xu, Fangjun Chen, Yang Yang, Weifeng Wang, Kai Wang, Lixia Yu, Jia Wei, Baorui Liu
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Advanced Science
Subjects:
gastric/gastroesophageal junction cancer
nanovaccine
neoantigens
PD‐1 blockade
personalized vaccine
prevent postoperative cancer recurrence and metastasis
Online Access:https://doi.org/10.1002/advs.202203298

Internet

https://doi.org/10.1002/advs.202203298

Similar Items